Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same

1. A compound according to formula (I):

in which:

R1 is selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkyl(C3-C7)cycloalkyl, CH2COR3, phenyl, and phenyl substituted with one or more substituents selected from the group consisting hydroxyl, halogen, and (C1-C6)alkyl;

R3 is a hydroxyl, (C1-C4)alkoxy, amino, (C1-C4)alkylamino or di(C1-C4)alkylamino group;

Ar1 is a radical selected from the group consisting of:

in which X is O or S; Y is CH 2 or NH; R 2 is selected from the group consisting of H, (C1-C6) alkyl and (CH2)nNR4R5; and R′ 2 is (CH2)nNR4R5;

R4 and R5 are each, independently of one another, a substituent selected from the group consisting of H, (C1-C4)alkyl, (C1-C6)alkyl(C3 -C7)cycloalky, (C3 -C7)cycloalkyl, C(═NH)NH 2 and SO 2 (C1-C6)alkyl; R5 can also be a CO—(C1-C4)alkyl, CO—(C3-C7)cycloalkyl, CO-aryl, SO 2 -aryl, tert-butoxycarbonyl or benzyloxycarbonyl group;

or R4 and R5, together with the nitrogen atom to which they are attached, constitute an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl radical, said radical being unsubstituted or substituted one or more times with a (C1-C6)alkyl, (C1-C4)alkyl-OH or COO(C1-C6)alkyl group;

Ar2 is a phenyl group which is unsubstituted or substituted from 1 to 5 times with the same or different substituents selected from the group consisting of a halogen atom, a (C1-C4)alkyl group, a trifluoromethyl group, and a (C1-C4)alkoxy group;

n represents 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein:

Ar1 is a radical selected from the group consisting of:

in which R 2 is CH 3 or (CH2)nNR4R5; and R′ 2 is CH2NR4R5, in which R 4 and R 5 are independently selected from the group consisting of H and (C1-C4)alkyl; and Y is CH 2 or NH;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein:

Ar2 is:

in which R 6 and R 7 are independently selected from the group consisting of H, CH 3 , OCH 3 , F, Cl and Br;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 3 , wherein:

Ar2 is:

in which R 6 and R 7 are independently selected from the group consisting of H, CH 3 , OCH 3 , F, Cl and Br;

or a pharmaceutically acceptable salt thereof.

5. A compound according to formula (I):

in which:

R1 is selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkyl(C3-C7)cycloalkyl, CH2COR3, phenyl, and phenyl substituted with hydroxyl and/or halogen and/or (C1-C6)alkyl;

R3 is a hydroxyl, (C1-C4)alkoxy, amino, (C1-C4)alkylamino or di(C1-C4)alkylamino group;

Ar1 is a radical selected from the group consisting of:

R 2 is CH 3 or (CH2)nNR4R5; R′ 2 is CH2NR4R5, in which R 4 and R 5 are independently selected from the group consisting of H and (C1-C6)alkyl; and Y is CH 2 or NH;

Ar2 is a phenyl group which is unsubstituted or substituted from 1 to 5 times with the same or different substituents selected from the group consisting of a halogen atom, a (C1-C4)alkyl group, a trifluoromethyl group and a (C1-C4)alkoxy group;

n represents 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

6. A compound selected from the group consisting of:

N-[2-(2,1,3-benzothiadiazol-4-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea;

N- [6-(2,6-dichlorophenyl)-2- [(1,3 -dihydro-2,2-dioxido-2, 1 -benzisothiazol-5 -yl)amino]pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea;

N-[6-(2,6-dichlorophenyl)-2-[(2-methyl-6-benzoxazolyl)amino]pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea;

N-[6-(2,6-dichlorophenyl)-2-[[2-[(diethylamino)methyl]-5-benzofuranyl]amino]pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea;

1,1-dimethylethyl [[5-[[6-(2,6-dichlorophenyl)-7-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-2-benzoxazolyl]methyl]carbamate;

N-[2-[[2-(aminomethyl)-5-benzoxazolyl]amino]-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-ylFN′-(1,1-dimethylethyl)urea;

N-[6-(2,6-dichlorophenyl)-2-(imidazo[1,2-a]pyridin-6-ylamino)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea;

N-[6-(2,6-dichlorophenyl)-2-([1,2,4]triazolo[1,5-a]pyridin-6-ylamino)pyrido[2,3-d]pyrimidin-7-ylFN′-(1,1-dimethylethyl)urea;

N-[2-(2,1,3-benzoxadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea; and

N-[2-(1,3-dihydro-2,2-dioxido-2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)urea;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising a compound according to claim 6 or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient.

9. The pharmaceutical composition according to claim 7 , further comprising at least one other anticancer active ingredient.